Navigation Links
Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit
Date:3/24/2009

DOYLESTOWN, Pa., March 24 /PRNewswire/ -- Avidas(TM) Pharmaceuticals, a privately held, specialty pharmaceutical company which focuses on dermatology and women's health, today announced the launch of Scalacort(TM) DK (defence kit), that offers three scalp solutions in one patient convenience kit.

Scalacort DK includes Scalacort (hydrocortisone lotion USP) 2%, a fast-drying, non-greasy, corticosteroid in a clear fragrance-free base. Scalacort relieves itching and inflammation of the scalp in areas where greasy ointments and creams may not be cosmetically appealing. For added patient convenience Scalacort DK also includes the following complimentary products: defence(TM) medicated shampoo, a professional-strength medicated shampoo formulated with 2% salicylic acid and 2% micronized colloidal sulfur to control the flaking and scaling of seborrheic dermatitis and scalp psoriasis; and defence(TM) gentle cleansing shampoo, a color- and fragrance-free, non-irritating shampoo designed to be used daily on all hair types. Scalacort DK is available by prescription only.

Seborrheic dermatitis (also known as seborrheic eczema) is one of the most common cutaneous disorders affecting approximately eight million Americans. According to the American Academy of Dermatology (AAD), seborrheic dermatitis cannot be cured but in most cases will respond quickly to proper treatment. The goals of treatment are to loosen and remove scales and crusts, prevent skin infections, as well as reduce the inflammation and itch. Scalp psoriasis, another common skin disorder affecting approximately four million Americans, shares the same treatment goals of removing scales and crusts along with reducing inflammation and itch.

"Patient convenience is important to treatment outcomes," said Millburn, New Jersey dermatologist Dr. Gail H. Mautner. "With Scalacort DK physicians can, with one prescription, provide their patients with three scalp products in a single convenience kit."

A valuable patient prescription co-pay coupon is available at http://www.ScalacortDK.com

About Scalacort:

Scalacort is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Important Safety Information:

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

Please see Scalacort full prescribing information at http://www.ScalacortDK.com

About Seborrheic Dermatitis:

Seborrheic dermatitis is a chronic inflammatory disorder affecting areas of the head and trunk where sebaceous glands are most prominent. Lipophilic yeasts of the Malassezia genus, as well as genetic, environmental and general health factors, contribute to this disorder. Scalp seborrhea varies from mild dandruff to dense, diffuse, adherent scale.

Facial and trunk seborrhea is characterized by powdery or greasy scale in skin folds and along hair margins.

About Scalp Psoriasis:

Psoriasis is a chronic, non-contagious autoimmune disease which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Skin rapidly accumulates at these sites and takes on a silvery-white appearance. Approximately half of the people who have psoriasis have scalp psoriasis.

About Avidas:

Avidas Pharmaceuticals is a privately held company focused on the therapeutic areas of dermatology and women's health. The company acquires, develops, and maximizes the potential of acquired products through focused selling and precision marketing. The Company is headquartered in Doylestown, PA. http://www.avidaspharma.com

Contact: Avidas Pharmaceuticals, LLC, Greg Gironda, 267-895-1755, greggironda@avidaspharma.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Avidas Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... support, and collaboration, announces Mirroring360 Pro . This new addition to the ... collaboration experience for education and business. , Mirroring360 Pro enables educators, business professionals ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... 18, 2017  Astute Medical, Inc., developer of biomarkers ... be presented at the 2017 National Kidney Foundation (NKF) ... continues through April 22. Physicians will present data on ... assess risk for acute kidney injury (AKI) during the ... Elevated levels of TIMP-2 and IGFBP-7 ...
Breaking Medicine Technology: